Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetylator phenotype in Behçet's disease.

Rafid A Najim1, Khalifa E Sharquie, Mahmood H Al-Janabi

  • 1Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.

The Journal of Dermatology
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Burn Hemangioma: A New Variant of Hemangioma.

Dermatology (Basel, Switzerland)·2021
Same author

Traction Alopecia: Clinical and Cultural Patterns.

Indian journal of dermatology·2021
Same author

COVID-19 infection is a major cause of acute telogen effluvium.

Irish journal of medical science·2021
Same author

Nevus depigmentosus: the analysis of 37 cases.

Italian journal of dermatology and venereology·2020
Same author

Psoriasis and vitiligo are close relatives.

Clinical, cosmetic and investigational dermatology·2017
Same author

Panniculitis is a common unrecognized histopathological feature of cutaneous leishmaniasis.

Indian journal of pathology & microbiology·2016

Behçet's disease (BD) patients exhibit a unique acetylator status, with a higher prevalence of slow or non-acetylators compared to healthy individuals. This acetylator status is linked to disease severity and HLA-B51 positivity.

Area of Science:

  • Pharmacogenomics
  • Immunology
  • Rheumatology

Background:

  • Behçet's disease (BD) is a complex inflammatory disorder with unclear pathogenesis.
  • Acetylation status, determined by drug metabolism, is known to vary among individuals.
  • Genetic factors, such as HLA-B51, are associated with BD susceptibility.

Purpose of the Study:

  • To investigate the acetylator status in patients with Behçet's disease.
  • To compare the acetylator status of BD patients with that of healthy individuals.
  • To explore the relationship between acetylator status, disease severity, and HLA-B51 in BD.

Main Methods:

  • A case-control study involving 41 BD patients and 37 healthy controls.
  • Oral administration of dapsone (100 mg) followed by plasma dapsone and monoacetyldapsone level determination via HPLC after 3 hours.

Related Experiment Videos

  • Assessment of HLA-B51, Clinical Manifestation Index (C.M.I.), and pathergy test in BD patients.

    • Main Results:

    • Healthy individuals showed 70.2% slow acetylators and 29.8% rapid acetylators.
    • BD patients exhibited 53.7% slow acetylators and 46.3% non-acetylators; no rapid acetylators were observed.
    • A significant negative association was found between slow/non-acetylator status and BD severity, with slow acetylators having more severe disease.
    • BD patients positive for HLA-B51 predominantly displayed slow or non-acetylator status.

    Conclusions:

    • Behçet's disease patients possess a distinct acetylator phenotype.
    • Acetylation status appears to be a significant factor influencing BD pathogenesis and clinical presentation.
    • These findings may inform future therapeutic strategies and understanding of BD etiology.